Who Qualifies for Saxenda? Complete Eligibility Guide

What Are the FDA's Official Criteria for Saxenda?

The FDA approved Saxenda in December 2014 for chronic weight management in adults, and expanded that approval to adolescents aged 12 to 17 in December 2020. The label sets out two separate BMI thresholds for adults: a BMI of 30 or above with no additional conditions, or a BMI of 27 or above paired with at least one weight-related comorbidity. These thresholds match the broader FDA framework for anti-obesity pharmacotherapy and align with guidance from the American Association of Clinical Endocrinology.

The full prescribing information is available directly from the FDA at accessdata.fda.gov [1].

Adult BMI Requirements in Detail

A BMI of 30 places a 5-foot-9-inch person at roughly 203 pounds. The 27-plus-comorbidity threshold is intentionally lower because excess weight combined with metabolic disease carries higher absolute cardiovascular risk than weight alone. Qualifying comorbidities listed in the FDA label include:

• Type 2 diabetes mellitus
• Hypertension (diagnosed or medication-managed)
• Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides)

Having one of these three conditions is sufficient. A patient does not need all three.

Adolescent-Specific Eligibility

For patients aged 12 to 17, the FDA requires a body weight above 60 kg and an initial BMI at or above the 95th percentile for age and sex. The 95th-percentile cutoff corresponds to the clinical definition of obesity in pediatric medicine, as outlined in CDC growth-chart data [2]. Adolescents with a BMI between the 85th and 94th percentile (overweight, not obese) do not meet the label criteria regardless of comorbidity status.

Saxenda is the only GLP-1 receptor agonist currently FDA-approved specifically for this adolescent age range in weight management, a distinction that matters when clinicians at programs like Calibrate are selecting agents for younger patients.

What Clinical Evidence Supports These Eligibility Thresholds?

The eligibility criteria are grounded in the SCALE trial program, a series of phase 3 randomized controlled trials that generated the efficacy and safety data Novo Nordisk submitted for FDA approval.

SCALE Obesity and Prediabetes Trial

The SCALE Obesity and Prediabetes trial (N=3,731) enrolled adults with a BMI of 30 or above, or a BMI of 27 or above with dyslipidemia or hypertension. At 56 weeks, participants receiving liraglutide 3 mg lost a mean of 8.4 kg (8.0% of body weight) compared with 2.8 kg (2.6%) in the placebo group (P<0.001) [3]. That 5.6 kg difference between arms was the primary basis for the label claim of clinically meaningful weight loss.

The trial also showed that 63.2% of liraglutide-treated participants lost at least 5% of body weight, versus 27.1% on placebo. Losing 5% of body weight is the threshold the FDA uses to define a "clinically meaningful" response in obesity pharmacotherapy.

SCALE Diabetes Trial

The SCALE Diabetes trial (N=846) focused on adults with type 2 diabetes and a BMI of 27 or above, directly mirroring the comorbidity arm of the FDA label. At 56 weeks, liraglutide 3 mg produced a mean weight loss of 6.0% versus 2.0% for placebo (P<0.001), alongside a 1.33% reduction in HbA1c compared with 0.38% for placebo [4]. This trial confirmed that patients qualifying under the comorbidity threshold still achieve meaningful metabolic benefit.

SCALE Adolescents Trial

The adolescent eligibility criteria come from the SCALE Adolescents trial (N=251), which enrolled patients aged 12 to 17 with a BMI at or above the 95th percentile and body weight above 60 kg. At 56 weeks, liraglutide 3 mg reduced BMI standard deviation score by 0.22 versus an increase of 0.22 in the placebo group, a treatment difference of 0.43 (P<0.001) [5]. The trial provided the statistical justification for setting the adolescent thresholds exactly where the label places them.

Who Does Not Qualify for Saxenda?

Understanding who is excluded is as clinically important as understanding who is included. Several contraindications appear in the FDA label and in guideline documents from the Endocrine Society.

Absolute Contraindications

The FDA label lists these as absolute contraindications [1]:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Known hypersensitivity to liraglutide or any excipient in the formulation
• Pregnancy (liraglutide is rated FDA Pregnancy Category X for this indication)

Rodent studies showed dose-dependent thyroid C-cell tumors with liraglutide, though human relevance is not established. The MTC and MEN 2 contraindications exist out of precaution. All prescribers are required to counsel patients about these risks as part of the FDA Risk Evaluation and Mitigation Strategy (REMS) for the GLP-1 class.

Relative Exclusions and Clinical Cautions

Clinicians at programs like Calibrate also typically exclude or closely supervise patients with:

• A personal history of pancreatitis (acute or chronic), given the class-wide signal for pancreatic inflammation
• Severe renal impairment (eGFR <15 mL/min/1.73 m2) or end-stage renal disease, where liraglutide has not been adequately studied
• Severe hepatic impairment
• Active gallbladder disease, because weight loss itself and GLP-1 agents both independently increase gallstone risk

The Endocrine Society's 2015 clinical practice guideline on pharmacological management of obesity states: "We suggest using weight-loss medications as an adjunct to lifestyle interventions and not as a substitute for them" [6]. That framing means a patient who declines lifestyle modification concurrently may not be an appropriate candidate even if they meet the BMI threshold.

BMI Below Threshold

A patient with a BMI of 26.9 and no qualifying comorbidity does not meet label criteria. This is not a relative caution. It is a labeling boundary. Off-label prescribing below BMI 27 does occur, but it falls outside FDA approval and requires individualized clinical justification.

How Does Calibrate Assess Saxenda Eligibility?

Calibrate is a metabolic health program that pairs GLP-1 medication with one-on-one video coaching. Their published eligibility framework aligns with the FDA label: a BMI of 30 or above, or a BMI of 27 or above with a qualifying condition. Calibrate physicians conduct a full intake that includes medical history, labs, and a synchronous video visit before writing any prescription.

The HealthRX clinical team has reviewed Calibrate's intake process and notes several evaluation points that go beyond the FDA label minimum:

1. A metabolic panel (fasting glucose, HbA1c, lipid panel, CMP) to confirm the presence or absence of comorbidities and to establish baseline values for monitoring
2. Thyroid function testing (TSH) given the liraglutide thyroid signal and the prevalence of subclinical hypothyroidism in patients with obesity
3. A structured cardiovascular risk screen, because some patients with very high 10-year ASCVD scores may benefit more rapidly from a semaglutide-based agent given the cardiovascular outcome data from LEADER (liraglutide 1.8 mg, N=9,340, 13% relative risk reduction in MACE) [7]
4. A behavioral readiness screen, consistent with the Endocrine Society guideline requirement for concurrent lifestyle modification

Programs that prescribe after a simple BMI check without labs or a clinical visit are not following standard-of-care evaluation practices.

What Comorbidities Count as Qualifying Conditions?

The FDA label names type 2 diabetes, hypertension, and dyslipidemia. Clinical practice at academic weight-management centers often applies a broader view based on the obesity medicine literature.

Conditions Explicitly Listed in the FDA Label

• Type 2 diabetes mellitus. Controlled or uncontrolled. The patient does not need to be failing other diabetes medications; the diagnosis alone qualifies.
• Hypertension. Defined as a systolic blood pressure of 130 mmHg or higher, or diastolic of 80 mmHg or higher, per the 2017 ACC/AHA guideline, or as currently managed with antihypertensive medication [8].
• Dyslipidemia. An LDL at or above 130 mg/dL, HDL below 40 mg/dL in men or below 50 mg/dL in women, or triglycerides at or above 150 mg/dL.

Conditions Not Explicitly Named but Commonly Considered

Obstructive sleep apnea, nonalcoholic fatty liver disease (NAFLD/NASH), and polycystic ovary syndrome (PCOS) appear in the American Association of Clinical Endocrinology's 2016 comprehensive clinical practice guidelines as weight-related comorbidities warranting pharmacotherapy consideration [9]. These conditions do not appear by name in the Saxenda label. A prescribing physician may use clinical judgment to treat them as qualifying conditions, but the FDA label does not require their presence.

How Does the Saxenda Qualification Process Compare to Other GLP-1 Agents?

Patients and clinicians often ask how Saxenda eligibility compares to that of semaglutide-based options (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro).

Wegovy (Semaglutide 2.4 mg)

Wegovy carries identical adult BMI thresholds to Saxenda: BMI of 30 or above, or BMI of 27 or above with at least one weight-related comorbidity. The qualifying comorbidities listed in the Wegovy label also match: hypertension, type 2 diabetes, dyslipidemia, with obstructive sleep apnea added explicitly in a 2024 label expansion following the SURMOUNT-OSA data [10]. In the STEP-1 trial (N=1,961), semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo (P<0.001) [11]. That magnitude of weight loss is roughly double the 8.0% seen with liraglutide 3 mg in the SCALE program, which clinicians weigh when choosing between agents.

Zepbound (Tirzepatide 2.5 to 15 mg)

Zepbound (tirzepatide), a dual GIP/GLP-1 receptor agonist, received FDA approval in November 2023 for the same adult BMI thresholds as Saxenda and Wegovy. In the SURMOUNT-1 trial (N=2,539), tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks versus 3.1% with placebo (P<0.001) [12]. Zepbound does not yet have an FDA-approved indication for adolescents.

Why Saxenda Might Still Be Chosen

Despite lower average weight loss in trials, Saxenda remains relevant for several reasons: longer post-marketing safety data (over a decade), the adolescent indication, lower monthly out-of-pocket cost in some insurance tiers, and availability in some markets where semaglutide supply remains constrained. The Endocrine Society guideline supports selecting among approved agents based on individual patient factors including cost, tolerability, comorbidity profile, and patient preference [6].

What Happens If You Meet the Criteria? The Dose Titration Schedule

Qualifying for Saxenda is the first step. Understanding the titration schedule helps patients set realistic expectations about when they will reach the therapeutic dose.

Week-by-Week Titration

The FDA-approved titration schedule is [1]:

• Weeks 1 to 2: 0.6 mg daily
• Weeks 3 to 4: 1.2 mg daily
• Weeks 5 to 6: 1.8 mg daily
• Weeks 7 to 8: 2.4 mg daily
• Week 9 onward: 3.0 mg daily (target therapeutic dose)

The gradual increase is designed to reduce gastrointestinal side effects, primarily nausea, vomiting, and diarrhea, which are the most common reasons for early discontinuation. In the SCALE Obesity and Prediabetes trial, 9.9% of liraglutide-treated participants discontinued because of adverse events versus 3.8% of placebo participants [3].

Monitoring After Starting

Patients who qualify and begin Saxenda should have their weight, blood pressure, heart rate, and fasting glucose checked at 16 weeks. If a patient has not lost at least 4% of baseline body weight by week 16 on the 3 mg dose, the FDA label recommends reassessing and considering discontinuation, because those patients are unlikely to achieve clinically meaningful benefit with continued treatment [1].

Key Questions Patients Ask Before Starting Saxenda

Patients who have identified themselves as potentially eligible often arrive with practical questions that go beyond the BMI table.

Does Insurance Cover Saxenda?

Coverage varies significantly by payer. Medicare Part D excluded obesity medications for decades, though the Treat and Reduce Obesity Act has been under ongoing legislative discussion. Many commercial plans now cover Saxenda with prior authorization that requires documentation of BMI and comorbidity status. Some plans require documented failure of a structured lifestyle program before approving the medication. Patients should request a benefits investigation from their pharmacy or prescriber's office before starting the intake process with any telehealth program.

Can You Qualify for Saxenda If You Have Type 1 Diabetes?

The FDA label does not explicitly approve Saxenda for type 1 diabetes. The SCALE trial program excluded patients with type 1 diabetes. Prescribing in this population is off-label and carries the added clinical complexity of hypoglycemia risk. The American Diabetes Association's 2024 Standards of Care in Diabetes do not recommend GLP-1 receptor agonists as primary pharmacotherapy for type 1 diabetes management [13].

What Labs Are Typically Required Before Prescribing?

There is no single FDA-mandated lab panel before initiating Saxenda, but standard clinical practice at weight-management programs includes:

• Fasting lipid panel (to document dyslipidemia if BMI is 27 to 29.9)
• Fasting glucose and HbA1c (to confirm or rule out type 2 diabetes)
• Basic metabolic panel (renal and hepatic function)
• TSH (given the thyroid C-cell signal and high prevalence of thyroid disease in the obesity population)
• Blood pressure measurement (to document or rule out hypertension)

Patients with a BMI of 30 or above technically do not need labs to confirm eligibility, but the labs provide the clinical baseline necessary for safe monitoring.